Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and keeps an Outperform rating on the shares. Protagonist Therapeutics is expected to see further clinical and regulatory catalysts through 2026-2027, including a potential Rusfertide approval in polycythemia vera in Q3 and advancing early-stage pipeline assets, supported by strong partnered program execution, meaningful milestone payments, and a solid cash position that reinforces its multi-shot oncology and immunology platform value, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
- Protagonist Therapeutics price target raised to $121 from $110 at Truist
- Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
- Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
- Protagonist price target raised to $110 from $107 at Leerink